Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
97.76
+2.95 (3.11%)
Nov 21, 2024, 1:28 PM EST - Market open
Blueprint Medicines Revenue
Blueprint Medicines had revenue of $128.18M in the quarter ending September 30, 2024, with 126.61% growth. This brings the company's revenue in the last twelve months to $434.42M, up 100.93% year-over-year. In the year 2023, Blueprint Medicines had annual revenue of $249.38M with 22.22% growth.
Revenue (ttm)
$434.42M
Revenue Growth
+100.93%
P/S Ratio
13.57
Revenue / Employee
$663,229
Employees
655
Market Cap
6.21B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 249.38M | 45.34M | 22.22% |
Dec 31, 2022 | 204.04M | 23.96M | 13.30% |
Dec 31, 2021 | 180.08M | -613.66M | -77.31% |
Dec 31, 2020 | 793.74M | 727.22M | 1,093.37% |
Dec 31, 2019 | 66.51M | 21.99M | 49.39% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elanco Animal Health | 4.45B |
R1 RCM | 2.46B |
RadNet | 1.77B |
Lantheus Holdings | 1.50B |
Merit Medical Systems | 1.33B |
Halozyme Therapeutics | 947.36M |
Corcept Therapeutics | 628.56M |
Cytokinetics | 3.22M |
BPMC News
- 5 days ago - Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs - Seeking Alpha
- 6 days ago - Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Benzinga
- 21 days ago - Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PRNewsWire
- 5 weeks ago - Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 - PRNewsWire
- 2 months ago - The Schall Law Firm Has Launched An Inquiry Into Whether Blueprint Medicines Corporation Violated Securities Laws And Impacted Investors Are Invited To Join - Accesswire
- 2 months ago - Blueprint Medicines Corporation Is Being Investigated For Securities Fraud And Stakeholders With Losses Should Contact The Schall Law Firm - Accesswire
- 2 months ago - Blueprint Medicines to Present at Upcoming Investor Conferences - PRNewsWire